Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Patient reported outcomes for telisotuzumab vedotin in c-Met protein overexpressing EGFR WT nonsquamous NSCLC

ESMO 2024

13 - 17 Sep 2024

Published: 14 Sep 2024

Views: 11

Rating:

Save

Prof Nicolas Girard - Institut Curie, Paris, France

Dr Nicolas Girard speaks to ecancer at ESMO 2024 about the patient reported outcome results from the LUMINOSITY trial. This trial evaluated telisotuzumab vedotin in patients with c-Met protein overexpressing, EGFR wildtype, non-squamous non-small cell lung cancer.

Lung cancer/treatment-related symptoms and impact on function and quality of life were evaluated using the EORTC quality of life questionnaires.

Dr Girard reports that patients treated with telisotuzumab vedotin reported improvement or maintenance in most patient-reported outcomes evaluated.

Related Videos

Breastfeeding after breast cancer is safe

Dr Eva Blondeaux - Ospedale San Martino, Genova, Italy

Breastfeeding after breast cancer is safe ( Dr Eva Blondeaux - Ospedale San Martino, Genova, Italy )

Adjuvant avelumab versus control does not significantly improve DFS but does...

Prof Pier Conte - University of Padova, Padova, Italy

Adjuvant avelumab versus control does not significantly improve DFS but does improve OS in high-risk TNBC patients ( Prof Pier Conte - University of Padova, Padova, Italy )

Rates of pathologic complete response after neoadjuvant datopotamab deruxtecan...

Dr Jane Lowe Meisel - Winship Canter Institute, Atlanta, USA

Rates of pathologic complete response after neoadjuvant datopotamab deruxtecan in neoadjuvant breast cancer ( Dr Jane Lowe Meisel - Winship Canter Institute, Atlanta, USA )

Grand Rounds: Improving quality of patient-centred care

Dr Didier Verhoeven, Prof Nirmala Bhoo Pathy and Dr Luzia Travado

Grand Rounds: Improving quality of patient-centred care ( Dr Didier Verhoeven, Prof Nirmala Bhoo Pathy and Dr Luzia Travado )

Pembrolizumab improves breast cancer outcomes regardless of age or menopausal...

Dr Javier Cortes - International Breast Cancer Center, Barcelona, Spain

Pembrolizumab improves breast cancer outcomes regardless of age or menopausal status ( Dr Javier Cortes - International Breast Cancer Center, Barcelona, Spain )

CAR-T therapy and impact to cancer patient outcomes and experience of treatment

Mr Matthias Hellberg-Naegele - Cantonal Hospital St Gallen, St Gallen...

CAR-T therapy and impact to cancer patient outcomes and experience of treatment ( Mr Matthias Hellberg-Naegele - Cantonal Hospital St Gallen, St Gallen, Switzerland )

KEYNOTE-756 trial shows increased response in ER+/HER2- breast cancer

Dr Fatima Cardoso - Champalimaud Cancer Center, Lisbon, Portugal

KEYNOTE-756 trial shows increased response in ER+/HER2- breast cancer ( Dr Fatima Cardoso - Champalimaud Cancer Center, Lisbon, Portugal )

Assessment of QoL results and correlation with survival outcomes in phase III...

Dr Alberto Servetto - University of Naples Federico II, Naples, Italy

Assessment of QoL results and correlation with survival outcomes in phase III clinical trials in metastatic NSCLC ( Dr Alberto Servetto - University of Naples Federico II, Naples, Italy )

Single-dose IORT during lumpectomy for breast cancer an innovative patient...

Dr Jayant Vaidya - University College London, London, UK

Single-dose IORT during lumpectomy for breast cancer an innovative patient-centred treatment ( Dr Jayant Vaidya - University College London, London, UK )

More from ecancer